A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer

• Published in: Investigational new drugs Vol. 29; no. 4; p. 674
• Main Authors: Chu, Franklin M, Picus, Joel, Fracasso, Paula M, Dreicer, Robert, Lang, Zhihui, Foster, Brenda
• Format: Journal Article
• Language: English
• Published: United States 01.08.2011
• Subjects: Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - blood; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Castration; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Integrin alphaV - immunology; Male; Middle Aged; Neoplasm Metastasis; Prednisone - administration & dosage; Prednisone - therapeutic use; Prostatic Neoplasms - drug therapy; Taxoids - administration & dosage; Taxoids - pharmacology; Taxoids - therapeutic use; Treatment Outcome

We evaluated the safety and efficacy of intetumumab in combination with docetaxel in patients with castrate-resistant metastatic prostate cancer. Patients and methods In this phase 1, open-label, multicenter, nonrandomized study, 75 mg/m² docetaxel was administered on Day 1 of each of nine 21-day tr...